Adriana Martinez-Pinto

Madrid, MD, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

New Diagnoses of Human Immunodeficiency Virus Infection in a Hospital Emergency Department: Clinical Characteristics and Factors Associated with Late Diagnosis.

New Diagnoses of Human Immunodeficiency Virus Infection in a Hospital Emergency Department: Clinical Characteristics and Factors Associated with Late Diagnosis.

Journal: The Journal of emergency medicine

Published: March 09, 2026

Effectiveness of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide in people with HIV with very high viral load (≥500 000 copies/mL).

Effectiveness of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide in people with HIV with very high viral load (≥500 000 copies/mL).

Journal: The Journal of antimicrobial chemotherapy

Published: March 04, 2026

Impact of Proviral-DNA M184V/I on 96-Week Outcomes of DTG/3TC Maintenance Therapy: Results From the VOLVER Clinical Trial.

Impact of Proviral-DNA M184V/I on 96-Week Outcomes of DTG/3TC Maintenance Therapy: Results From the VOLVER Clinical Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: October 19, 2025

Impact of antiretroviral regimens containing integrase inhibitors on achieving viral suppression at ultra-low levels compared to other antiretroviral therapy strategies.

Impact of antiretroviral regimens containing integrase inhibitors on achieving viral suppression at ultra-low levels compared to other antiretroviral therapy strategies.

Journal: AIDS (London, England)

Published: June 11, 2025

Dolutegravir/Lamivudine for Maintenance of Virological Suppression in Persons With Historical Suspected or Confirmed Resistance to Lamivudine: Week 48 Results of a Single-Arm, Open-Label, Multicenter, Phase IIa Clinical Trial.

Dolutegravir/Lamivudine for Maintenance of Virological Suppression in Persons With Historical Suspected or Confirmed Resistance to Lamivudine: Week 48 Results of a Single-Arm, Open-Label, Multicenter, Phase IIa Clinical Trial.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: November 12, 2024

Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians.

Non-suppressible viraemia during HIV-1 therapy: a challenge for clinicians.

Journal: The lancet. HIV

Published: February 23, 2024

Mitochondrial Haplogroups and Weight Gain After Initiating ART in Patients With HIV.

Mitochondrial Haplogroups and Weight Gain After Initiating ART in Patients With HIV.

Journal: The Journal of infectious diseases

Published: December 21, 2023

Association of Cardiac Troponin T With Coronary Atherosclerosis in Asymptomatic Primary Prevention People With HIV.

Association of Cardiac Troponin T With Coronary Atherosclerosis in Asymptomatic Primary Prevention People With HIV.

Journal: JACC. Advances

Published: December 12, 2023

Deep Sequencing on Proviral DNA: More Questions than Answers.

Deep Sequencing on Proviral DNA: More Questions than Answers.

Journal: Journal of acquired immune deficiency syndromes (1999)

Published: May 31, 2023

Cabotegravir and rilpivirine for the treatment of HIV.

Cabotegravir and rilpivirine for the treatment of HIV.

Journal: Expert review of anti-infective therapy

Published: March 14, 2020

Showing 1-10 of 10

Last Updated: 09/26/2026